Mar. 18 at 10:24 PM
$AVXL
Has anyone given serious thought that Anavex is evaluating multiple M&A type offers? Despite a number of missteps along this journey we know the CEO and BOD are shrewd and understand what they are sitting on. Gotta believe a decision regarding this will be made post EMA and FDA decisions. Approval clearly generates a transaction in multiples of rejection and even rejection w an imminent new AD trial gets you double digit billions. The pipeline is extensive, potential indications vast, market oppty huge, cost to produce minimal, likely priced to treat all & an oral method of delivery. And ofc, the science proven and compelling. Why sit on
$125M for 4 years? Why bring on new BoD members and senior leaders? Is it Leverage? Sort of a pay me or I’ll play type negotiation.
The next few months will be interesting. Patients, caregivers need to be at the front. The rest follow.
GLTA.
